Nalaganje...
Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin
AIMS: Lobeglitazone has been developed for the treatment of type 2 diabetes mellitus. This study was conducted to evaluate potential drug–drug interactions between lobeglitazone and warfarin, an anticoagulant with a narrow therapeutic index. METHODS: In this open-label, three-treatment, crossover st...
Shranjeno v:
| izdano v: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2015
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4354432/ https://ncbi.nlm.nih.gov/pubmed/25767371 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S76591 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|